ArticleVaccine: X2023

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.

Rapisa Nantanee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.